Disease burden and changing trends of bladder cancer in China and globally in 1992 - 2021
10.3969/j.issn.1006-2483.2026.03.002
- VernacularTitle:1992—2021年中国及全球膀胱癌疾病负担及变化趋势分析
- Author:
Zhengnan LI
1
;
Zhuang LI
2
;
Yuanyuan LUO
3
;
Bo YU
3
;
Hao SU
3
;
GuangYong CAO
1
;
Kai YIN
1
;
Dongbo YUAN
3
;
Jianguo ZHU
4
Author Information
1. Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China;Graduate School of Zunyi Medical University, Zunyi, Guizhou 563099, China
2. Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China;Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China
3. Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China
4. Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China;Graduate School of Zunyi Medical University, Zunyi, Guizhou 563099, China;Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China
- Publication Type:Journal Article
- Keywords:
Bladder cancer;
Burden of disease;
GBD database;
China;
Global
- From:
Journal of Public Health and Preventive Medicine
2026;37(3):8-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the disease burden and trends of bladder cancer in China and globally from 1992 to 2021. Methods Using the GBD 2021 database, the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates of bladder cancer in China and globally from 1992–2021 were analyzed. Average annual percentage change (AAPC) was calculated using Joinpoint regression. Subgroup analyses by sex and age were conducted, and a Bayesian age-period-cohort (BAPC) model was used to predict trends in age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) for the next 15 years. Results In 2021, China reported 106 000 new cases (ASIR: 5.14/100 000), 571 000 prevalent cases (age-standardized prevalence rate, ASPR: 26.61/100 000), 43 000 deaths (ASMR: 2.34/100 000), and a DALY rate of 45.31/100 000. From 1992–2021, China showed upward trends in ASIR and ASPR but declines in ASMR and DALYs, while global ASIR, ASMR, and DALYs decreased overall with slow ASPR growth. The peak cases in China and globally were both concentrated in the 65-79 age group, with a significantly higher burden on males than females. In China, smoking-related ASMR and ASDR exceeded global averages and rose, whereas high glucose-related indexes were lower and declined. Projections for 2021–2036 indicated that the global incidence and mortality rates would be rising, but ASIR/ASPR would be declining, while in China, the incidence rate would continue to rise, and the mortality rate will stabilize, with a significant increase in ASIR and a gradual decrease in ASPR. Conclusion From 1992 to 2021, the incidence of bladder cancer in China has shown a continuous upward trend and is projected to persist in the future, with significant gender and age differences. Particular attention should be given to elderly males aged 85-89. The disease burden of bladder cancer attributable to smoking continues to rise, highlighting the urgent need to strengthen tobacco control policies.
